Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 in Combination with Libtayo® to be Reported at ASCO
Dupixent® Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc.
Dupixent® sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
